2018年恶性淋巴瘤综合治疗进展

2018 overview and treatment of malignant lymphoma

淋巴瘤是起源于淋巴造血系统的恶性肿瘤。近年来我国淋巴瘤发病率呈上升趋势,目前居各类癌症的第8位。多年来,为改善淋巴瘤患者的临床转归,专家们在开发新的药物、技术和方法的同时,也在对传统治疗方案进行挑战。本文将总结全球2018年恶性淋巴瘤治疗新进展。

Lymphoma is a malignant tumor originated from lymphopoietic system.In recent years,the incidence of lymphoma in China has been on the rise,ranking 8th among all kinds of cancers.Over the years,experts have both been challenging traditional therapies and developing new drugs,the techniques and methods to improve clinical outcomes in patients with lymphoma.This paper will summarize the new progress in the treatment of malignant lymphoma worldwide in 2018.